Cold-EEZE(R) Lozenges not Affected by FDA Advisory for Zicam(R) Intra-Nasal Products
June 16 2009 - 5:35PM
PR Newswire (US)
DOYLESTOWN, Pa., June 16 /PRNewswire-FirstCall/ -- The U.S. Food
and Drug Administration (FDA) today advised consumers to stop using
three intra-nasal products (gels and swabs) marketed
over-the-counter as cold remedies under the Zicam(R) brand because
the use of these intra-nasal products are associated with the loss
of sense of smell (a condition called anosmia). While these
products are manufactured with a zinc ingredient, The Quigley
Corporation (NASDAQ:QGLY), http://www.quigleyco.com/, maker of the
popular line of Cold-EEZE(R) zinc gluconate lozenges, assures
consumers that their oral zinc lozenge products are not involved in
this new FDA advisory, and that the Cold-EEZE(R) brand continues to
be supported as safe and effective in clinical research. Only
intra-nasal products have shown any association with anosmia. "The
introduction of zinc ions orally has not been connected with the
loss of smell," says Darrell T. Hulisz, R.Ph., PharmD, clinical
pharmacist/researcher and associate clinical professor at Ohio
Northern University College of Pharmacy. "The safe and efficacious
use of oral zinc gluconate lozenges is well established." "The FDA
has made a determination that the Zicam intra-nasal products have a
growing body of evidence suggesting that they may pose a safety
risk to consumers who use them," says Albert Piechotta, executive
director of communications at The Quigley Corporation. "Cold-EEZE
zinc lozenges have been shown to safely reduce the duration and
severity of cold symptoms by nearly half in two clinical studies
and have no history of causing adverse events related to anosmia in
clinical studies or safety studies." Since their introduction 14
years ago, Cold-EEZE lozenges have had an outstanding record of
safety. Customers can be assured that Cold-EEZE lozenges will
continue to be available and is not affected by the FDA's decision
to request Zicam remove its nasal products from store shelves." For
more information about Cold-EEZE(R), visit
http://www.coldfight360.com/. About The Quigley Corporation The
Quigley Corporation (NASDAQ:QGLYNASDAQ:http://www.Quigleyco.com) is
a diversified natural health medical science company. Its Cold
Remedy segment is a leading marketer and manufacturer of the
COLD-EEZE(R) family of lozenges, gums and sugar free tablets
clinically proven to cut the common cold nearly in half. COLD-EEZE
customers include leading national wholesalers and distributors, as
well as independent and chain food, drug and mass merchandise
stores and pharmacies. The Quigley Corporation has several wholly
owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA
approved facilities to manufacture COLD- EEZE(R) lozenges as well
as fulfill other contract manufacturing opportunities. Quigley
Pharma Inc. (http://www.quigleypharma.com/) conducts research in
order to develop and commercialize a pipeline of patented botanical
and naturally derived potential prescription drugs. Forward-Looking
Statements Certain statements in this press release are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 and involve known and
unknown risk, uncertainties and other factors that may cause the
Company's actual performance or achievements to be materially
different from the results, performance or achievements expressed
or implied by the forward-looking statement. Factors that impact
such forward-looking statements include, among others, changes in
worldwide general economic conditions, changes in interest rates,
government regulations, and worldwide competition. Media Contact:
Alyson O'Mahoney Robin Leedy & Associates (914) 241-0086, ext.
13 or Albert Piechotta, Executive Director of Communications The
Quigley Corporation (215) 345-0919, ext. 122 Investor Relations
Contact: Carl Hymans G.S. Schwartz & Co. 212-725-4500-ext 304
DATASOURCE: Quigley Corporation CONTACT: Media: Alyson O'Mahoney,
Robin Leedy & Associates, +1-914-241-0086, ext. 13, or Albert
Piechotta, Executive Director of Communications, The Quigley
Corporation, +1-215-345-0919, ext. 122; or Investor Relations: Carl
Hymans, G.S. Schwartz & Co., +1-212-725-4500-ext 304, Web Site:
http://www.quigleyco.com/
Copyright